Recent Updates
Recently added Catalysts

End Stage Renal Disease: one US-listed biotech with a clinical-stage programme

Cardiovascular & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$166Muniverse median $1.20B
Allocated capital$83M$166M competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank279/299crowding rank 279

End Stage Renal Disease is uncontested. Humacyte (HUMA) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Acellular Tissue Engineered Vessel in phase 3.

There is no public comparable to price it against. HUMA spreads its $166M market cap across 2 indications, so $83M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$83M of allocated capital sits in End Stage Renal Disease, ranking it 279th of 299 indications by the money committed to it.

Companies developing drugs for End Stage Renal Disease 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
HUMAHumacyteAcellular Tissue Engineered VesselPhase 31$166MNo2 1 Nov 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why End Stage Renal Disease counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. End Stage Renal Disease has one competitor and a median of $166M.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Coronary Artery Disease1 company · $83M · median $166MUncontestedVenous Leg Ulcers1 company · $170M · median $170MUncontestedAnemia Associated With Chronic Kidney Disease1 company · $180M · median $1.6BUncontestedArrhythmogenic Right Ventricular Cardiomyopathy2 companies · $210M · median $277MOrphan cornerGout1 company · $211M · median $211MUncontestedGestational Diabetes1 company · $424M · median $1.3BUncontestedChronic Idiopathic Constipation1 company · $462M · median $924MUncontestedLong Chain Fatty Acid Oxidation Disorders1 company · $488M · median $1.5BUncontested

End Stage Renal Disease pipeline questions

Which biotech companies are developing drugs for End Stage Renal Disease?

Humacyte (HUMA, Acellular Tissue Engineered Vessel, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in End Stage Renal Disease.

How advanced is the End Stage Renal Disease pipeline?

Of the 1 clinical-stage programme in End Stage Renal Disease, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for End Stage Renal Disease?

No. HUMA is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in End Stage Renal Disease, which is why the indication is classified as uncontested.

When is the next End Stage Renal Disease catalyst?

The next dated catalyst in End Stage Renal Disease is HUMA on 1 Nov 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map